Prabhudas Lilladher Recommends 'BUY' on Aster DM Healthcare; Target Rs 715

• Prabhudas Lilladher maintains a 'BUY' rating for Aster DM Healthcare with a revised target price of Rs 715 per share.
• Aster DM Healthcare's Q3 consolidated EBITDA grew 10% year-on-year to Rs 2.14 billion, slightly below estimates due to lower growth in the Karnataka cluster.
• Quality Care (QCIL) showed impressive growth of 32% year-on-year in Q3, significantly exceeding expectations.
• The board approved a merger with Quality Care (QCIL), positioning the combined entity as India's third-largest healthcare chain by revenue and bed capacity.
• Positive outlook based on post-merger synergies, improved occupancy, margin expansion, and planned bed additions.

Why It Matters: Prabhudas Lilladher recommends buying Aster DM Healthcare, citing strong growth prospects post-merger with QCIL.